From the Division of Neurosurgery (J.C.K.).
Neuroendovascular Program (A.A.D., J.E.V., R.W.R., C.J.S., A.B.P.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
AJNR Am J Neuroradiol. 2023 Mar;44(3):297-302. doi: 10.3174/ajnr.A7796. Epub 2023 Feb 16.
Middle meningeal artery embolization is an emerging treatment option for chronic subdural hematomas.
Our aim was to assess outcomes following middle meningeal artery embolization by different techniques, including in comparison with traditional surgical methods.
We searched the literature databases from inception to March 2022.
We selected studies reporting outcomes after middle meningeal artery embolization as a primary or adjunctive treatment for chronic subdural hematoma.
We analyzed the risk of recurrence of chronic subdural hematoma, reoperation for recurrence or residual hematoma, complications, and radiologic and clinical outcomes using random effects modeling. Additional analyses were performed on the basis of whether middle meningeal artery embolization was used as the primary or adjunct treatment and by embolic agent type.
Twenty-two studies were included with 382 patients with middle meningeal artery embolization and 1373 surgical patients. The rate of subdural hematoma recurrence was 4.1%. Fifty (4.2%) patients underwent a reoperation for a recurrent or residual subdural hematoma. Thirty-six (2.6%) experienced postoperative complications. The rates of good radiologic and clinical outcomes were 83.1% and 73.3%, respectively. Middle meningeal artery embolization was significantly associated with decreased odds of subdural hematoma reoperation (OR = 0.48; 95% CI, 23.4-99.1; = .047) compared with surgery. The lowest rates of subdural hematoma radiologic recurrence, reoperation, and complications were observed among patients receiving embolization with Onyx, whereas good overall clinical outcome occurred most commonly with combined polyvinyl alcohol and coils.
A limitation was the retrospective design of studies included.
Middle meningeal artery embolization is safe and effective, either as a primary or adjunctive treatment. Treatment using Onyx seems to yield lower rates of recurrence, rescue operation, and complications whereas particles and coils produce good overall clinical outcomes.
中脑膜动脉栓塞是慢性硬脑膜下血肿的一种新兴治疗选择。
我们旨在评估不同技术的中脑膜动脉栓塞治疗的结果,包括与传统手术方法的比较。
我们从创建到 2022 年 3 月搜索了文献数据库。
我们选择了报告中脑膜动脉栓塞作为慢性硬脑膜下血肿的主要或辅助治疗后结果的研究。
我们使用随机效应模型分析了慢性硬脑膜下血肿复发、因复发或残留血肿而再次手术、并发症以及影像学和临床结果的风险。根据中脑膜动脉栓塞是作为主要治疗还是辅助治疗以及栓塞剂类型进行了额外分析。
共纳入 22 项研究,其中 382 例患者接受中脑膜动脉栓塞治疗,1373 例患者接受手术治疗。硬脑膜下血肿复发率为 4.1%。50 例(4.2%)患者因复发或残留硬脑膜下血肿而行再次手术。36 例(2.6%)患者发生术后并发症。影像学和临床结果良好的比例分别为 83.1%和 73.3%。与手术相比,中脑膜动脉栓塞与降低硬脑膜下血肿再次手术的可能性显著相关(OR=0.48;95%CI,23.4-99.1;=0.047)。在接受 Onyx 栓塞的患者中,硬脑膜下血肿影像学复发、再次手术和并发症的发生率最低,而联合聚乙烯醇和线圈的治疗则最常获得良好的总体临床结局。
纳入研究的设计存在局限性。
中脑膜动脉栓塞是一种安全有效的治疗方法,无论是作为主要治疗还是辅助治疗。使用 Onyx 似乎可以降低复发、挽救手术和并发症的发生率,而颗粒和线圈则产生良好的总体临床结局。